In 12–17% of the muscle-invasive bladder carcinomas (MIBC) and in 10% of the non-muscle-invasive bladder carcinomas, PPARγ focal amplifications leading to PPARγ overexpression have been reported, suggesting a role for PPARγ in the initiation and maintenance of bladder cancer. Here, PPARG is linked to urinary bladder carcinoma.